Stocks · News reference
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
Read original at benzinga-SEC Filing
Read original at benzingaFiled: 2026-08-12 AccNo: 0001628280-26-056198 Size: 213 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarAllogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share
Read original at benzinga